Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.01
PBH's Cash to Debt is ranked lower than
63% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.62 vs. PBH: 0.01 )
PBH' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.01

Equity to Asset 0.22
PBH's Equity to Asset is ranked higher than
51% of the 61 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.42 vs. PBH: 0.22 )
PBH' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.48
Current: 0.22

0.2
0.48
Interest Coverage 2.75
PBH's Interest Coverage is ranked lower than
55% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.02 vs. PBH: 2.75 )
PBH' s 10-Year Interest Coverage Range
Min: 1.69   Max: 9999.99
Current: 2.75

1.69
9999.99
F-Score: 4
Z-Score: 1.07
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.30
PBH's Operating margin (%) is ranked higher than
97% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.73 vs. PBH: 28.30 )
PBH' s 10-Year Operating margin (%) Range
Min: -55.89   Max: 56.28
Current: 28.3

-55.89
56.28
Net-margin (%) 8.47
PBH's Net-margin (%) is ranked higher than
89% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.25 vs. PBH: 8.47 )
PBH' s 10-Year Net-margin (%) Range
Min: -61.61   Max: 29.21
Current: 8.47

-61.61
29.21
ROE (%) 9.25
PBH's ROE (%) is ranked higher than
66% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.14 vs. PBH: 9.25 )
PBH' s 10-Year ROE (%) Range
Min: -48.3   Max: 14.88
Current: 9.25

-48.3
14.88
ROA (%) 2.60
PBH's ROA (%) is ranked higher than
58% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.17 vs. PBH: 2.60 )
PBH' s 10-Year ROA (%) Range
Min: -20.19   Max: 4.11
Current: 2.6

-20.19
4.11
ROC (Joel Greenblatt) (%) 212.02
PBH's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 25.75 vs. PBH: 212.02 )
PBH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -396.48   Max: 332.66
Current: 212.02

-396.48
332.66
Revenue Growth (3Y)(%) 19.80
PBH's Revenue Growth (3Y)(%) is ranked higher than
84% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.50 vs. PBH: 19.80 )
PBH' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 84.1
Current: 19.8

0
84.1
EBITDA Growth (3Y)(%) 27.10
PBH's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.20 vs. PBH: 27.10 )
PBH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 59.1
Current: 27.1

0
59.1
EPS Growth (3Y)(%) 33.80
PBH's EPS Growth (3Y)(%) is ranked higher than
84% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 17.30 vs. PBH: 33.80 )
PBH' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 230.2
Current: 33.8

0
230.2
» PBH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PBH Guru Trades in Q4 2013

Columbia Wanger 1,740,000 sh (New)
John Keeley 933,159 sh (+9.12%)
Ken Fisher 1,521,300 sh (+2.25%)
Joel Greenblatt 196,849 sh (+0.38%)
Wallace Weitz 150,000 sh (unchged)
Ken Heebner 550,000 sh (unchged)
Murray Stahl 101,396 sh (-2.17%)
Jim Simons 520,500 sh (-21.39%)
Paul Tudor Jones 8,766 sh (-55.95%)
Steven Cohen 8,119 sh (-73.77%)
» More
Q1 2014

PBH Guru Trades in Q1 2014

Joel Greenblatt 289,984 sh (+47.31%)
John Keeley 985,159 sh (+5.57%)
Ken Fisher 1,524,150 sh (+0.19%)
Columbia Wanger 1,740,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Ken Heebner Sold Out
Murray Stahl 100,636 sh (-0.75%)
Wallace Weitz 125,000 sh (-16.67%)
» More
Q2 2014

PBH Guru Trades in Q2 2014

Murray Stahl 100,713 sh (+0.08%)
Wallace Weitz 125,000 sh (unchged)
John Keeley 943,159 sh (-4.26%)
Ken Fisher 1,426,675 sh (-6.4%)
Columbia Wanger 754,000 sh (-56.67%)
Joel Greenblatt 48,774 sh (-83.18%)
» More
Q3 2014

PBH Guru Trades in Q3 2014

Paul Tudor Jones 11,918 sh (New)
Joel Greenblatt 420,370 sh (+761.87%)
Wallace Weitz 160,000 sh (+28%)
Ken Fisher 1,448,650 sh (+1.54%)
Murray Stahl 100,851 sh (+0.14%)
Columbia Wanger 740,000 sh (-1.86%)
John Keeley 844,159 sh (-10.5%)
» More
» Details

Insider Trades

Latest Guru Trades with PBH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 761.87%0.12%$30.79 - $35.83 $ 35.215%420370
Wallace Weitz 2014-09-30 Add 28%0.03%$30.79 - $35.83 $ 35.215%160000
Joel Greenblatt 2014-06-30 Reduce -83.18%0.1%$26.38 - $35.29 $ 35.2110%48774
Ken Heebner 2014-03-31 Sold Out 0.51%$26.34 - $35.8 $ 35.2118%0
Joel Greenblatt 2014-03-31 Add 47.31%0.04%$26.34 - $35.8 $ 35.2118%289984
Private Capital 2013-09-30 Sold Out 0.65%$29.25 - $35.56 $ 35.217%0
Wallace Weitz 2013-09-30 Reduce -40%0.12%$29.25 - $35.56 $ 35.217%150000
Joel Greenblatt 2013-09-30 Add 55.78%0.07%$29.25 - $35.56 $ 35.217%196103
Private Capital 2013-06-30 Reduce -66.42%1.2%$25.7 - $30.31 $ 35.2125%236944
John Keeley 2013-06-30 New Buy0.49%$25.7 - $30.31 $ 35.2125%842159
Joel Greenblatt 2013-06-30 Add 56%0.06%$25.7 - $30.31 $ 35.2125%125883
Private Capital 2013-03-31 Reduce -32.54%0.68%$19.87 - $25.78 $ 35.2153%705621
Ken Heebner 2013-03-31 Add 1000%0.31%$19.87 - $25.78 $ 35.2153%550000
Joel Greenblatt 2013-03-31 Add 398.23%0.09%$19.87 - $25.78 $ 35.2153%80694
John Paulson 2013-03-31 Sold Out 0.08%$19.87 - $25.78 $ 35.2153%0
Private Capital 2012-12-31 Reduce -30.6%0.67%$16.51 - $21.6 $ 35.2183%1045996
Wallace Weitz 2012-12-31 Add 25%0.04%$16.51 - $21.6 $ 35.2183%250000
Ken Heebner 2012-12-31 New Buy0.03%$16.51 - $21.6 $ 35.2183%50000
John Paulson 2012-12-31 Reduce -23.53%0.03%$16.51 - $21.6 $ 35.2183%650000
Joel Greenblatt 2012-12-31 New Buy0.02%$16.51 - $21.6 $ 35.2183%16196
John Burbank 2012-12-31 Sold Out 0.01%$16.51 - $21.6 $ 35.2183%0
Private Capital 2012-09-30 Reduce -24.56%0.61%$15.37 - $17.03 $ 35.21116%1507137
John Burbank 2012-09-30 New Buy0.01%$15.37 - $17.03 $ 35.21116%10410
Ken Fisher 2012-09-30 Add 22.86%0.01%$15.37 - $17.03 $ 35.21116%1586225
Wallace Weitz 2012-06-30 Reduce -42.86%0.11%$13 - $17.76 $ 35.21133%200000
Joel Greenblatt 2012-06-30 Sold Out 0.09%$13 - $17.76 $ 35.21133%0
Ken Fisher 2012-06-30 New Buy0.06%$13 - $17.76 $ 35.21133%1291079
Jean-Marie Eveillard 2012-06-30 Sold Out 0.01%$13 - $17.76 $ 35.21133%0
John Paulson 2012-03-31 New Buy0.12%$11.21 - $17.7 $ 35.21158%1000000
Joel Greenblatt 2012-03-31 Add 51.85%0.03%$11.21 - $17.7 $ 35.21158%59007
Jean-Marie Eveillard 2012-03-31 New Buy0.01%$11.21 - $17.7 $ 35.21158%127618
George Soros 2011-12-31 Sold Out 0.0016%$8.33 - $11.68 $ 35.21250%0
Private Capital 2011-09-30 Add 12.59%0.18%$8.37 - $13.44 $ 35.21222%2134609
Joel Greenblatt 2011-09-30 Add 102.41%0.03%$8.37 - $13.44 $ 35.21222%35256
George Soros 2011-09-30 New Buy$8.37 - $13.44 $ 35.21222%10200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Prestige Brands Holdings Inc

Meridian Funds Comments on Prestige Brands - Sep 08, 2014

Prestige Brands (PBH) is the largest independent provider of over-the-counter products in North America. Examples of their brands include Chloraseptic, Dramamine, PediaCare and Efferdent, to name a few. We added to the position during the first quarter when the stock was one of the largest detractors, selling off for short-term reasons. The company experienced a decline in items stocked at one of the company’s largest customers, but we believe this is a temporary situation and our long- term thesis remains unchanged. This proved timely as the company demonstrated stabilized results during the second quarter and announced an acquisition, which drove the stock higher. Prestige Brands has an asset-light business model that focuses exclusively on the marketing and distribution of these brands, which results in a growing, scalable and high-return business model. We continue to hold the position.

From Meridian Funds (Trades, Portfolio)’ Meridian Growth Fund Second Quarter 2014 Commentary.

Check out Meridian Funds latest stock trades

Top Ranked Articles about Prestige Brands Holdings Inc

Meridian Funds Comments on Prestige Brands
Prestige Brands (PBH) is the largest independent provider of over-the-counter products in North America. Examples of their brands include Chloraseptic, Dramamine, PediaCare and Efferdent, to name a few. We added to the position during the first quarter when the stock was one of the largest detractors, selling off for short-term reasons. The company experienced a decline in items stocked at one of the company’s largest customers, but we believe this is a temporary situation and our long- term thesis remains unchanged. This proved timely as the company demonstrated stabilized results during the second quarter and announced an acquisition, which drove the stock higher. Prestige Brands has an asset-light business model that focuses exclusively on the marketing and distribution of these brands, which results in a growing, scalable and high-return business model. We continue to hold the position. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 35.30
PBH's P/E(ttm) is ranked higher than
66% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 26.20 vs. PBH: 35.30 )
PBH' s 10-Year P/E(ttm) Range
Min: 7.85   Max: 492.31
Current: 35.3

7.85
492.31
P/B 3.10
PBH's P/B is ranked higher than
69% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.03 vs. PBH: 3.10 )
PBH' s 10-Year P/B Range
Min: 0.54   Max: 3.6
Current: 3.1

0.54
3.6
P/S 3.00
PBH's P/S is ranked higher than
56% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.95 vs. PBH: 3.00 )
PBH' s 10-Year P/S Range
Min: 0.67   Max: 3.07
Current: 3

0.67
3.07
PFCF 16.50
PBH's PFCF is ranked higher than
89% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 49.94 vs. PBH: 16.50 )
PBH' s 10-Year PFCF Range
Min: 3.11   Max: 20.34
Current: 16.5

3.11
20.34
EV-to-EBIT 19.93
PBH's EV-to-EBIT is ranked higher than
72% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.48 vs. PBH: 19.93 )
PBH' s 10-Year EV-to-EBIT Range
Min: -4.3   Max: 20.2
Current: 19.93

-4.3
20.2
PEG 1.39
PBH's PEG is ranked higher than
85% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.85 vs. PBH: 1.39 )
PBH' s 10-Year PEG Range
Min: 0   Max: 18.27
Current: 1.39

0
18.27
Shiller P/E 217.90
PBH's Shiller P/E is ranked higher than
66% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 42.91 vs. PBH: 217.90 )
PBH' s 10-Year Shiller P/E Range
Min: 190.63   Max: 878.5
Current: 217.9

190.63
878.5
Current Ratio 1.99
PBH's Current Ratio is ranked higher than
81% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.54 vs. PBH: 1.99 )
PBH' s 10-Year Current Ratio Range
Min: 1.7   Max: 3.98
Current: 1.99

1.7
3.98
Quick Ratio 1.25
PBH's Quick Ratio is ranked higher than
76% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.13 vs. PBH: 1.25 )
PBH' s 10-Year Quick Ratio Range
Min: 1.08   Max: 3.05
Current: 1.25

1.08
3.05

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.90
PBH's Dividend Yield is ranked lower than
86% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.55 vs. PBH: 0.90 )
PBH' s 10-Year Dividend Yield Range
Min: 0.87   Max: 1.18
Current: 0.9

0.87
1.18
Dividend Payout 0.31
PBH's Dividend Payout is ranked higher than
75% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.63 vs. PBH: 0.31 )
PBH' s 10-Year Dividend Payout Range
Min: 5.22   Max: 5.22
Current: 0.31

Yield on cost (5-Year) 0.90
PBH's Yield on cost (5-Year) is ranked lower than
88% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.80 vs. PBH: 0.90 )
PBH' s 10-Year Yield on cost (5-Year) Range
Min: 0.87   Max: 1.18
Current: 0.9

0.87
1.18
Share Buyback Rate -1.30
PBH's Share Buyback Rate is ranked higher than
63% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: -0.20 vs. PBH: -1.30 )
PBH' s 10-Year Share Buyback Rate Range
Min: 0   Max: -23.5
Current: -1.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 12.10
PBH's Price/DCF (Projected) is ranked higher than
66% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.50 vs. PBH: 12.10 )
PBH' s 10-Year Price/DCF (Projected) Range
Min: 0.38   Max: 97.16
Current: 12.1

0.38
97.16
Price/Median PS Value 1.70
PBH's Price/Median PS Value is ranked higher than
55% of the 71 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.33 vs. PBH: 1.70 )
PBH' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 1.78
Current: 1.7

0.49
1.78
Earnings Yield (Greenblatt) 5.00
PBH's Earnings Yield (Greenblatt) is ranked higher than
68% of the 62 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.70 vs. PBH: 5.00 )
PBH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.9   Max: 13.7
Current: 5

4.9
13.7

Analyst Estimate

Mar15 Mar16
Revenue(Mil) 698 801
EPS($) 1.81 2.20
EPS without NRI($) 1.81 2.20

Business Description

Industry: Medical Distribution » Medical Distribution
Compare:LRLCY, KMB, RBGPF, EL, UNLRY » details
Traded in other countries:PBV.Germany,
Prestige Brands Holdings Inc is incorporated in the State of Delaware in 1996. The Company sells healthcare, household cleaning and personal care products in North America. It conducts its operations through two main business segments Over-the-Counter Healthcare and Household Cleaning. The Company's portfolio of Over-the-Counter (OTC) Healthcare products includes 14 core brands, including five from the GSK Brands acquisitions. Its core OTC brands are Chloraseptic sore throat remedies, Clear Eyes eye drops, Compound W wart removers, Little Remedies and PediaCare pediatric healthcare products, The Doctor's brand of oral care products, Efferdent and Effergrip denture products, Luden's drops, Dramamine motion sickness products, BC and Goody's analgesic powders, Beano gas prevention, Gaviscon antacids, and Debrox ear drops. Its other significant brands include Dermoplast first-aid products, Murine eye and ear care products, NasalCrom allergy prevention relief product, New-Skin liquid bandage, Wartner wart removers, Fiber Choice fiber laxative supplements, and Ecotrin aspirin. The Company's portfolio of household cleaning brands includes the Comet, Chore Boy and Spic and Span brands. Comet was originally introduced in 1956 and is recognized household cleaning brands. Chore Boy scrubbing pads and sponges were initially launched in the 1920's. Chore Boy products are currently sold in food and drugs stores, mass merchandisers, and in hardware and convenience stores. Competitors in the OTC Healthcare category include Johnson & Johnson; McNeil-PPC Tylenol(r) and Novartis Consumer Healthcare, each of which competes with its PediaCare and Little Remedies brands; The Procter & Gamble Company, maker of Vicks(r), and Reckitt Benckiser, maker of Cepacol(r), each of which competes with its Chloraseptic brand; Kraft Foods, maker of Halls(r), which competes with ourLuden's brand; The Procter & Gamble Company, maker of Fixodent(r), and GlaxoSmithKline, maker of Polident(r), each of which competes with its Efferdent brand; and Insight Pharmaceuticals, Inc., maker of Bonine(r), which competes with its Dramamine brand. Sunstar America, Inc., maker of the GUM(r) line of oral care products, as well as DenTek(r) Oral Care, Inc., which markets a dental protector for nighttime teeth grinding and interdental toothpicks, competes with its The Doctor's oral care brand. Competitors in the Household Cleaning category include: Henkel AG & Co., maker of Ajax(r) Cleanser, and The Clorox Company, maker of Tilex(r), each of which competes with its Comet brand. Additionally, Clorox's Pine Sol(r) and The Procter & Gamble Company's Mr. Clean(r) compete with its Spic and Span brand, while 3M Company, maker of Scotch-Brite(r),O-Cel-O(r) and Dobie(r) brands, and Clorox's SOS(r), compete with its Chore Boy brand. The Company is subject to a variety of other regulations in various foreign markets, including regulations pertaining to import/export regulations and antitrust iss
» More Articles for PBH

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Prestige Brands Sep 08 2014 
Meridian Growth Fund Second Quarter 2014 Commentary Sep 08 2014 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Private Capital Management Sells Update Nov 27 2013 
Gold Guru John Paulson Drops Gold ABX in First Quarter Sells May 18 2013 
comment on PBH Jan 10 2013 
comment on PBH Jan 10 2013 
Weekly CEO Sells Highlight: Smiths News, Prestige Brands Holdings, Proto Labs, Imax Corp Nov 26 2012 
Why I'd Never Pay More Than Book Value for Nokia (NOK) Apr 12 2012 
Prestige Brands Holdings Inc. Reports Operating Results (10-Q) Feb 09 2011 

More From Other Websites
NYSE stocks posting largest percentage decreases Dec 22 2014
PRESTIGE BRANDS HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Dec 12 2014
PRESTIGE BRANDS HOLDINGS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits Nov 19 2014
Will This Ratings Upgrade Have a Positive Affect on Prestige Brands (PBH) Stock Today? Nov 18 2014
Prestige Brands Holdings, Inc. to Present at Morgan Stanley Global Consumer Conference Nov 18 2014
PRESTIGE BRANDS HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Nov 18 2014
Prestige Brands Holdings, Inc. to Present at Morgan Stanley Global Consumer Conference Nov 18 2014
PRESTIGE BRANDS HOLDINGS, INC. Financials Nov 14 2014
Prestige Brands Holdings, Inc. Reports Second Quarter Revenue Up 8.6%; Integration of Insight... Nov 11 2014
10-Q for Prestige Brands Holdings, Inc. Nov 09 2014
Prestige Brands Holdings Nov 06 2014
Prestige Brands Holdings Inc Earnings Call scheduled for 8:30 am ET today Nov 06 2014
Q2 2015 Prestige Brands Holdings Inc Earnings Release - Before Market Open Nov 06 2014
Prestige Brands beats Street 2Q forecasts Nov 06 2014
Prestige Brands beats Street 2Q forecasts Nov 06 2014
PRESTIGE BRANDS HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 06 2014
Prestige Brands Holdings, Inc. Reports Second Quarter Revenue Up 8.6%; Integration of Insight... Nov 06 2014
Goody’s Expands Partnership with NASCAR’s Dale Earnhardt Jr. Through 2017 Oct 27 2014
Goody’s Expands Partnership with NASCAR’s Dale Earnhardt Jr. Through 2017 Oct 27 2014
Zacks Investment Ideas feature highlights: Greenbrier, Jamba, Prestige Brands and FelCor Lodging... Oct 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK